Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.85 |
| ▸ | MEN1 | O00255 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.85 |
| ▸ | TUBB | P07437 | 5/20 | 0.85 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.85 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.85 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.85 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.85 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.85 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.85 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.85 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.85 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.85 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.85 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.85 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.85 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roseamine SCHEMBL30368397 | 1.00 | MAPT (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL15941262 | 0.95 | TUBB4A (0.79) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL285304 | 0.94 | LMNA (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL29385187 | 0.94 | LMNA (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL12213867 | 0.93 | MAPT (0.83) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL12237564 | 0.93 | MAPT (0.83) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL10018533 | 0.93 | MAPT (0.83) | MAPTMEN1KMT2ALMNATUBB4A | |
| SCHEMBL12451436 | 0.93 | MAPT (0.73) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL29376135 | 0.93 | MAPT (0.85) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinepidine SCHEMBL4076 | 0.93 | MAPT (0.85) | MAPTMEN1KMT2ALMNATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130273031-A1 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF | INST RECH PIERRE FABRE (FR) | 2013-10-17 | — | — | US | disclosed |
| US-8101180-B2 | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2012-01-24 | — | — | US | disclosed |
| US-7914784-B2 | Insulin-like growth factor I receptor (IGF-IR) specific monoclonal antibodies for diagnosis, prevention and treatment of cell proliferative disorders | PIERRE FABRE MEDICAMENT (FR) | 2011-03-29 | — | — | US | disclosed |
| US-20110014122-A1 | NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2011-01-20 | — | — | US | disclosed |
| US-7553485-B2 | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2009-06-30 | — | — | US | disclosed |
| US-20080286198-A1 | Novel anti-IGF-IR antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080193445-A1 | Novel anti-IGF-IR antibodies and uses thereof | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080063639-A1 | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies | PIERRE FABRE MEDICAMENT (FR) | 2008-03-13 | — | — | US | disclosed |
| US-7241444-B2 | Anti-IGF-IR antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193445-A1 | Novel anti-IGF-IR antibodies and uses thereof | IGF1R, EGFR, IRS1 | MAPT 3675/4885MEN1 1824/4885KMT2A 3395/4885 |
| US-20110014122-A1 | NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF | IGF1R, EGFR, INSR | MAPT 3785/4885MEN1 1599/4885KMT2A 3792/4885 |
| US-20080063639-A1 | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies | IGF1R, IGFBP1, IGFBP2 | MAPT 2465/4885MEN1 4206/4885KMT2A 4630/4885 |
| US-20130273031-A1 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF | IGF1R, EGFR, IRS1 | MAPT 3675/4885MEN1 1824/4885KMT2A 3395/4885 |
| US-20080286198-A1 | Novel anti-IGF-IR antibodies and uses thereof | IGF1R, EGFR, IRS1 | MAPT 3675/4885MEN1 1824/4885KMT2A 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.